Uqba Khan Farman Ali Muhammad Siddique Khurram Awais Zaka Tarik Hadid
10.1186/s40425-017-0214-9
J Immunother Cancer
2017 Feb 21;5:15.
autoimmune hemolytic anemia immunotherapy ipilimumab nivolumab
CC BY
https://pubmed.ncbi.nlm.nih.gov/28239468/
Anemia, Hemolytic, Autoimmune / chemically induced Antibodies, Monoclonal / adverse effects Antineoplastic Agents, Immunological / adverse effects Ipilimumab / adverse effects
Anemia, Hemolytic, Autoimmune / chemically induced Antibodies, Monoclonal / adverse effects Antineoplastic Agents, Immunological / adverse effects Ipilimumab / adverse effects Case Reports Adult CTLA-4 Antigen / antagonists & inhibitors Female Humans Immunotherapy / adverse effects Melanoma / drug therapy Nivolumab Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / drug therapy Antibodies, Monoclonal Antineoplastic Agents, Immunological CTLA-4 Antigen CTLA4 protein, human Ipilimumab PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
PMC5319184
28239468
Immunotherapy-associated autoimmune hemolytic anemia
2017